

This is the peer reviewed version of the following article:

Phosphorylation-dependent degradation of MEF2C contributes to regulate G2/M transition / Badodi, Sara; Baruffaldi, Fiorenza; Ganassi, Massimo; Battini, Renata; Molinari, Susanna. - In: CELL CYCLE. - ISSN 1538-4101. - 14:10(2015), pp. 1517-1528. [10.1080/15384101.2015.1026519]

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

14/12/2025 20:41

(Article begins on next page)

# Phosphorylation-dependent degradation of MEF2C contributes to regulate G2/M transition

Sara Badodi, Fiorenza Baruffaldi, Massimo Ganassi, Renata Battini, and Susanna Molinari

## QUERY SHEET

This page lists questions we have about your paper. The numbers displayed at left can be found in the text of the paper for reference. In addition, please review your paper as a whole for correctness.

- Q1. Au: Please confirm you have submitted your publication costs form.
- Q2. Au: Please provide revised history dates.
- Q3. Au: The volume and page numbers for Ref. “[15,23]” have been inserted using data from CrossRef.

## TABLE OF CONTENTS LISTING

The table of contents for the journal will list your paper exactly as it appears below:

**Phosphorylation-dependent degradation of MEF2C contributes to regulate G2/M transition**  
Sara Badodi, Fiorenza Baruffaldi, Massimo Ganassi, Renata Battini, and Susanna Molinari

# Phosphorylation-dependent degradation of MEF2C contributes to regulate G2/M transition

Sara Badodi<sup>1</sup>, Fiorenza Baruffaldi<sup>1</sup>, Massimo Ganassi<sup>2</sup>, Renata Battini<sup>1</sup>, and Susanna Molinari<sup>1,\*</sup>

<sup>1</sup>Dipartimento di Scienze della Vita; Università di Modena e Reggio Emilia; Modena, Italy; <sup>2</sup>Dipartimento di Scienze Biomediche; Metaboliche e Neuroscienze; Università di Modena e Reggio Emilia; Modena, Italy

**Keywords:** APC/C, cell cycle, degradation, MEF2, mitosis, muscle, phosphorylation, proliferation, splicing

**Abbreviations:** APC/C, Anaphase Promoting Complex/Cyclosome; CDK, Cyclin Dependent Kinase; CHX, Cycloheximide; CRC, ColoRectal Cancer; Gadd45b, Growth Arrest and DNA Damage b; degnon, degradation signal; HDAC, Histone Deacetylases; MADS, Minichromosome maintenance, Agamous, Deficiens, Serum response factor; MEF2, Myocyte Enhancer Factor 2; MyHC, Myosin Heavy Chain; UPS, Ubiquitin Proteasome System.

The Myocyte Enhancer Factor 2C (MEF2C) transcription factor plays a critical role in skeletal muscle differentiation, promoting muscle-specific gene transcription. Here we report that in proliferating cells MEF2C is degraded in mitosis by the Anaphase Promoting Complex/Cyclosome (APC/C) and that this downregulation is necessary for an efficient progression of the cell cycle. We show that this mechanism of degradation requires the presence on MEF2C of a D-box (R-X-X-L) and 2 phospho-motifs, pSer98 and pSer110. Both the D-box and pSer110 motifs are encoded by the ubiquitous alternate  $\alpha 1$  exon. These two domains mediate the interaction between MEF2C and CDC20, a co-activator of APC/C. We further report that in myoblasts, MEF2C regulates the expression of G2/M checkpoint genes (*14-3-3 $\gamma$* , *Gadd45b* and *p21*) and the sub-cellular localization of CYCLIN B1. The importance of controlling MEF2C levels during the cell cycle is reinforced by the observation that modulation of its expression affects the proliferation rate of colon cancer cells. Our findings show that beside the well-established role as pro-myogenic transcription factor, MEF2C can also function as a regulator of cell proliferation.

## Introduction

MEF2 proteins are members of the MADS (MCM1, Agamous, Deficiens and SRF) family of transcription factors that in vertebrates comprises 4 members, MEF2A-D. All MEF2 proteins share an N-terminal MADS box and an adjacent MEF2 domain that are required for MEF2 proteins homo- and hetero-dimerization and high-affinity DNA binding to the consensus sequence (C/T TA(A/T)<sub>4</sub>TAG/A) within the regulatory regions of target genes. The C-terminal regions of MEF2 factors contain transcription activation domains and are subject to complex patterns of alternative splicing. MEF2s are expressed in many tissues and organs where they control the activation of their differentiation programs.<sup>1</sup> MEF2 proteins are highly expressed in skeletal muscle where they play a pivotal role in terminal differentiation but they are unable to activate myogenesis alone; instead, these factors work in concert with the MYOD family of myogenic determinants, synergistically promoting myofiber differentiation.<sup>2-4</sup> Genetic studies in mouse and zebrafish have shown that among *Mef2* genes, *Mef2c* plays a unique role in the late phases of myogenesis, where it is essential for myofibers maturation.<sup>5,6</sup> Despite the well established role in terminal differentiation, *Mef2c* transcripts and protein are already detected in primary mouse

myoblasts.<sup>7,8</sup> To date most models suggest that MEF2 proteins exhibit no specific functions in myoblasts, but exist to “prime” muscle cells for differentiation when the environmental conditions become permissive (for example cessation of cellular proliferation signals). Consequently, we and other have proposed several mechanisms contributing to the silencing of the pro-myogenic activity of MEF2C in proliferating myoblasts. Mechanisms mediating this negative regulation include post-translational modifications leading to increased physical interaction with inhibitors such as class II HDACs and PIN1, reduced DNA binding capabilities and/or protein stability.<sup>9-11</sup> Besides, in vertebrates, a fundamental role in MEF2C activity regulation is played by alternative splicing processes.<sup>12-14</sup> In mammals 3 major exons are alternatively spliced in MEF2A, MEF2D or MEF2C: the 2 mutually exclusive exons  $\alpha 1$  and  $\alpha 2$ , a short exon  $\beta$  and an exon  $\gamma$ , which is only spliced in some MEF2C gene transcripts. In muscle cells the alternate inclusion in *Mef2c* transcripts of the ubiquitous  $\alpha 1$  or muscle-specific  $\alpha 2$  exon has a particular relevance in regulating the pro-myogenic activity of the encoded protein.<sup>15,16</sup> The recent observation that MEF2C $\alpha 1$ , present in proliferating myoblasts, is devoid of myogenic activity suggests that this “priming model” cannot be applied to this splice variant and indicate some novel functions of MEF2C in myoblasts.

\*Correspondence to: Susanna Molinari; Email: susanna.molinari@unimore.it

Submitted: 01/29/2015; Accepted: 03/01/2015

<http://dx.doi.org/10.1080/15384101.2015.1026519>

Indeed, in other cell types, *Mef2c* stimulates proliferation and regulate the expression of growth-related genes.<sup>17-22</sup> Furthermore, recently *Mef2c* has been shown to regulate cell cycle related-genes in muscle cells.<sup>23</sup> Therefore, in the attempt to investigate this unexplored activity, we found that the level of MEF2C protein fluctuates during the cell cycle and we describe a novel mechanism by which the Anaphase Promoting Complex/Cyclosome (APC/C) ubiquitin ligase controls MEF2C abundance. The functional relevance of this mechanism during the cell cycle is suggested by the observation that ectopic expression of a MEF2C mutant, resistant to APC/C-dependent degradation, impairs entry into mitosis and cell proliferation. Furthermore, modulation of *Mef2c* expression in colon cancer cells affects their proliferation rates. We also demonstrate that MEF2C, directly or indirectly, controls the expression of genes that regulate G2/M transition (*Gadd45B*, *P21* and *14.3.3 γ*)<sup>24-26</sup> and CYCLIN B1 sub-cellular localization. In summary, we present evidence that MEF2C plays a role in the transcriptional control of cell cycle-related genes and its degradation in mitosis contributes to the G2/M checkpoint inactivation in growing myoblasts.

## Results


### The ubiquitin-proteasome system (UPS) regulates MEF2C protein level during the cell cycle

MEF2C function in terminal differentiation of skeletal muscle has been well established, on the contrary little is known about its role in proliferating muscle cells. To investigate this issue, we used the C2 mouse cell line, derived from adult muscle cells, the satellite cells.<sup>27</sup> C2 cells proliferate as mononucleated myoblasts in high-serum medium, then terminally differentiate to multinucleated myotubes upon serum withdrawal. As shown in **Figure 1A**, MEF2C is already present in C2 myoblasts where also MYOD is expressed, as previously described.<sup>28</sup> MEF2C level raises upon terminal differentiation, concomitantly with the expression of MYOSIN HEAVY CHAIN (MyHC) and MYOGENIN, a well established MEF2C target.<sup>29</sup> To start evaluating a potential role of MEF2C in growing cells, we determined if the cell cycle might have an impact on MEF2C protein level, as it is reported for several genes that influence cellular proliferation. To address this issue, we synchronized C2 muscle cells in G0/G1, S, G2 and M phase. Western blot analysis confirmed that C2 cells were highly synchronized in our experimental conditions, as attested by the appearance of CYCLIN A as DNA synthesis proceeds and of Histone H3 phosphorylated on Serine 10 during mitosis (pH3(Ser10), **Fig. 1B**). The distribution of cells in the different phases was measured by flow cytometry analysis after propidium iodide staining (**Fig. 1B** lower table, **Fig. S1A**). To analyze the expression of *Mef2c* in the course of the cell cycle, proteins and mRNA extracts were prepared from synchronized myoblasts. Western blot analysis revealed that the level of MEF2C protein is high in G0/G1, S and G2 phases, whereas it is largely decreased and exhibits a lower electrophoretic mobility in M phase cells compared to the other phases of the cell cycle

(**Fig. 1B**). To further verify the efficacy of our synchronization protocol of C2 myoblasts, we also examined the protein level of the key myogenic regulators MYOD and MYF5. As shown in **Figure S1B**, the expression pattern of MEF2C during the cell cycle resembles that already described for MYF5,<sup>30-32</sup> whereas, as expected, MYOD protein level was very low in G0/G1 and only slightly reduced in M phase cell extracts.<sup>33-35</sup> The mitotic down-regulation profile of endogenous MEF2C was also observed in a non muscle cell line, the mouse NIH-3T3 fibroblasts (**Fig. S1C**). C2 synchronized extracts were further analyzed by quantitative PCR (RT-qPCR). While the amounts of MEF2C protein significantly decreased during the M phase, the level of *Mef2c* mRNA was higher if compared to the other phases suggesting that post-transcriptional mechanisms must be involved in the downregulation of MEF2C. Treatment of asynchronous C2 cells with the proteasome inhibitor MG132 prevented MEF2C protein down-regulation in a dose-dependent manner (**Fig. 1D**), suggesting that its decrease in mitosis is at least partially due to proteasome-dependent degradation. Proteasome targets are usually modified by the covalent addition of poly-ubiquitin chains. To test whether MEF2C is poly-ubiquitinated, C2 cells were co-transfected with FLAG-MEF2C and HA-ubiquitin expression plasmids. After inhibition of the proteasome, we immunoprecipitated FLAG-MEF2C proteins and observed by Western blot with the anti-HA antibody the presence of poly-ubiquitinated forms of MEF2C (**Fig. 1E**). When HA-ubiquitin was transfected with an empty vector (EV), no product was detected. Overall these data indicate that in myoblasts MEF2C undergoes an increased protein degradation in mitosis and that this downregulation is due to the UPS system.

### Role of phosphorylation in MEF2C degradation


We next explored the regulatory mechanism that triggered MEF2C degradation. Our data indicate that MEF2C protein decreases when cells pass through mitosis, whereas mRNA remains unaffected, and that the residual mitotic MEF2C protein has a lower electrophoretic mobility. Therefore we wanted to determine if a mitosis-specific post-translational modification might be necessary for MEF2C degradation. We considered that phosphorylation of Ser98 and Ser110 were likely candidates as modifications involved in MEF2C degradation, as phospho-Ser98 and phospho-Ser110 are binding sites for PIN1, a peptidyl prolyl cis-trans isomerase that regulates MEF2C protein stability.<sup>10</sup> Notably, Ser110 is located within a domain encoded by the  $\alpha 1$  exon, that is included in *Mef2c* transcripts alternatively to exon  $\alpha 2$  (see **Fig. 2A**). In agreement with previous data,<sup>15</sup> our results indicate that proliferating myoblasts express only the transcript encoding the MEF2C  $\alpha 1$  isoform, containing both Ser98 and Ser110, as determined by reverse transcription PCR (RT-PCR), using 2 common primers (**Fig. 2A**) that give 2 isoform-specific amplicons with different electrophoretic mobilities and that are differently susceptible to enzymatic restriction (**Fig. S2**). We evaluated the level of phosphorylation of these serines during the cell cycle using 2 antibodies that recognize MEF2C when phosphorylated on Ser98 (pSer98 MEF2C) or Ser110 (pSer110 MEF2C). As shown in **Figure 2C**, the variations of the signals of



**Figure 1.** MEF2C protein level is downregulated in mitosis and is targeted for degradation by the Ubiquitin-Proteasome Pathway. **(A)** MEF2C is expressed in proliferating myoblasts. Total protein extracts from C2 growing myoblasts (Mb) or differentiated myotubes (Mt) were analyzed by Western blot with antibodies against myosin heavy chain (MyHC), MYOGENIN, MYOD and MEF2C. Actin was used as loading control. **(B)** MEF2C protein level decreases in mitotic cells. C2 cells were grown asynchronously in high serum medium (Asyn), arrested in G0/G1 by incubation in methionine-depleted medium, synchronized in S by treatment with aphidicoline or incubated with Nocodazole before shake off treatment to generate a mitotic fraction (Shake off fraction; M) and a non-mitotic fraction (adherent; G2). Cell lysates obtained from synchronized cell populations were analyzed by Western blot assay with antibody against MEF2C. Antibodies specific for CYCLIN A and histone H3 phosphorylated on Ser10 (pH3(Ser10)) were used to verify the level of synchronization in S and M phases obtained with the treatments. Vinculin was used as loading control. DNA content was assessed by flow cytometry analysis, percentage of distribution in G0/G1, S and G2/M phase are reported (lower panel). **(C)** Analysis of *Mef2c* transcripts during the cell cycle. Total RNA was isolated from synchronized populations obtained as in A and *Mef2c* mRNA level was quantified by RT-qPCR. The ratio between *Mef2c* and *Gapdh* transcripts was calculated in each synchronized cell population. Value obtained for asynchronous C2 was arbitrarily set equal to 1. Histograms report the mean of 2 independent experiments  $\pm$  SEM. \* and \*\* represent *P*-values  $\leq$  0.05 and  $\leq$  0.01 respectively. **(D)** MEF2C is degraded by the proteasome. C2 proliferating myoblasts were incubated with increasing concentrations of the proteasome inhibitor MG132 (25  $\mu$ M or 50  $\mu$ M) from a stock in DMSO, the control sample received an equivalent volume of DMSO. After 4 hours of treatment cells were harvested and protein extracts were analyzed by Western blotting with anti-MEF2C specific antibody. Vinculin was used as a loading control. Lower panel shows the results of the densitometric quantification of the signals obtained with the anti-MEF2C antibody normalized for the total amount of protein. The quantity of MEF2C protein in MG132 treated cells is expressed relative to the quantity of MEF2C in the control sample (DMSO) taken as 1. **(E)** MEF2C is poly-ubiquitinated in proliferating myoblasts. CoIP and Western blot assays of lysates from C2 cells transiently transfected with vectors coding for FLAG-MEF2C and increasing amounts of HA-ubiquitin (HA-Ub) or Empty Vector (EV) as control. Thirty hours after transfection cells were treated with MG132 and then harvested. Anti-FLAG antibody was used for immunoprecipitation (IP $\alpha$ FLAG), anti-FLAG and anti-HA for Western blot detection of total Input and of immunoprecipitated proteins (IP $\alpha$ FLAG). Western blot results shown in B, D and E are representative of 2 independent experiments showing similar profiles.

175 phospho-Ser110 reflects the fluctuations of the MEF2C protein  
 during the cell cycle (compare to Fig. 2C), indicating a steady  
 state level of MEF2C phosphorylation on this residue through-  
 out the cell cycle. By contrast, in mitotic cells Ser98 phospho-  
 180 rylation is most abundant although the global level of MEF2C  
 protein is the lowest (Fig. 2C and Fig. 1B). Densitometric quan-  
 tification revealed a fold7- increase of pSer98 MEF2C signal

normalized to the total amount of MEF2C protein in mitosis  
 compared to asynchronous cells (Fig. 2C, lower panel). To deter-  
 mine the protein kinase(s) that regulate Ser98 and Ser110 phos-  
 phosphorylation, we carried out a kinase phosphorylation profiling  
 that revealed a preferential ability of the peptide containing 185  
 Ser110 to act as a substrate for the CDK5/p35 and CDK6/  
 Cdc2 protein kinases (Fig. S3A). On the contrary the peptide



**Figure 2.** Ser98 phosphorylation of MEF2C peaks in mitosis, triggers poly-ubiquitination of the protein and reduces its stability. **(A)** Schematic of the MEF2C isoforms in the exon 3 region, with the location of the primers used to detect the alternate  $\alpha 1$  and  $\alpha 2$  exons indicated (arrows). The amino acid sequences of the  $\alpha$  exons of the mouse protein are indicated below. The positioning of Ser98 and Ser110 phosphoacceptor sites in  $\alpha 1$  exon (and the residue equivalent to Ser98 in  $\alpha 2$  exon) are highlighted in red. **(B)** Exclusive inclusion of the  $\alpha 1$  exon in Mef2c transcripts in growing myoblasts. Total RNA was isolated from C2 myoblasts (Mb) or C2 cells that were differentiated for various lengths of time (0–72h). Exon expression was detected by RT-PCR using common primer (indicated in A) located on exons 2 and 4 that give rise to amplification products with different electrophoretic mobility. Amplification of plasmid vectors containing the murine cDNAs of the MEF2C  $\alpha 1$  and  $\alpha 2$  splice variants were used as controls of the correct size of expected amplicons ( $\alpha 1$  and  $\alpha 2$  sample lanes). Rplp0 was used as endogenous control. **(C)** MEF2C is highly phosphorylated on Ser98 in mitotic cells. Cell lysates of asynchronous (Asyn) or synchronized cells were analyzed by Western blot with polyclonal antibodies that recognize the phosphorylated Serine 98 (pSer98) or Serine 110 (pSer110) of MEF2C. Vinculin was used as loading control. The levels of Ser98 and Ser110 phosphorylation, evaluated by densitometric scanning, were normalized to the quantity of MEF2C protein (see Fig. 1B). In the histogram below are reported the phosphorylation grades of the 2 residues in synchronized cells, expressed relative to the value obtained in asynchronous cells, taken as 1. **(D)** Ser98 and Ser110 phosphorylation triggers MEF2C poly-poly-ubiquitination. C2 myoblasts were transiently transfected with expression vectors for HA-ubiquitin and FLAG-tagged wild type (WT) or not phosphorylatable MEF2C 2SA mutant where Ser98 and Ser110 are substituted with alanines. Anti-FLAG antibody was used for immunoprecipitation (IP $\alpha$ FLAG), anti-HA for Western immunoblot detection (IB). **(E)** The non-phosphorylatable MEF2C mutant proteins on Ser98 and Ser110 are more stable than the wild type protein. FLAG MEF2C wild type or mutated singularly on Ser98 (S98A), Ser110 (S110A) or both phosphoacceptor sites (2SA) were overexpressed in COS1 cells. After 36 h, protein synthesis was blocked with cycloheximide, the amount of FLAG MEF2C remaining at different times was checked by Western blot. Protein loading was controlled by anti-vinculin staining. The intensity of FLAG signal was quantified by densitometric analysis. The graph reports average of the intensity of MEF2C signals, relatively to the not treated sample (CHX 0h), of 2 independent experiments. Bars represent SEM. Western blot results reported in C and D are representative of 2 independent experiments that showed similar profiles.

containing Ser98 was not efficiently phosphorylated by any tested  
 190 kinases. The proximity of Ser98 and Ser110 led us to examine  
 their importance as reciprocal “priming” sites. To verify this  
 hypothesis we singularly substituted each of the 2 serines with  
 alanine and assayed the effects of these mutations on the phos-  
 phosphorylation of the wild type residue in proliferating cells. As  
 195 shown in Figure S3B, mutation on Ser98 did not alter the effi-  
 ciency of Ser110 phosphorylation whereas Ser98 phosphoryla-  
 tion is strongly impaired (35% less) when Ser110 is substituted  
 with an Alanine. This data suggest a mechanism whereby phos-  
 phosphorylation of MEF2C on Ser110 is necessary for the subsequent  
 200 Ser98 phosphorylation by a yet unknown mitotic kinase. The  
 hypothesis of a M phase-specific phosphorylation of MEF2C on  
 Ser98 is reinforced by the observed co-localization of pSer98


MEF2C in cells that are positive for Histone H3 phosphorylated  
 on Ser10 (Fig. S4).

Next we observed that phosphorylation of Ser98 and Ser110  
 205 promotes MEF2C poly-ubiquitination, given that the formation  
 of MEF2C-Ubiquitin conjugates is strongly impaired with the  
 protein mutated on the phosphoacceptor sites (MEF2C 2SA)  
 (Fig. 2D). Coherently with these findings, we found that the lack  
 of MEF2C phosphorylation on Ser98 and Ser110 increases the  
 210 stability of MEF2C in proliferating cells: in cycloheximide  
 (CHX)-treated COS cells the half-lives of single (S98A, S110A)  
 or double (2SA) not phosphorylatable MEF2C mutants are  
 increased if compared to that of the wild type protein (half life  
 8 hours) (Fig. 2E). Altogether our data indicate that a G1 phase  
 215 kinase, likely CDK6/CycD1, phosphorylates MEF2C on

Ser110, priming the protein for the subsequent mitosis-specific phosphorylation on Ser98 that ultimately promotes its degradation through the UPS.

### CDH1 or CDC20 mediate the degradation of MEF2C

The finding that the level of MEF2C protein decreases during mitosis, suggest that its degradation might be mediated by APC/C, an ubiquitin ligase complex that is responsible for degradation of several protein during this phase of the cell cycle. The activity of APC/C is controlled by 2 related activators, CDC20 and CDH1, that contain a C-terminal WD40 repeat domain, their main function being the recruitment of substrates to APC/C.<sup>36</sup> To verify our hypothesis, we first tested if MEF2C physically interacts with CDC20 and CDH1. To this aim, HEK293T cells were transfected with FLAG-MEF2C wild type or the non-phosphorylatable FLAG-MEF2C 2SA mutant and HA-tagged CDC20 or CDH1, the whole cell extracts were immunoprecipitated with anti-HA, and the interaction revealed by Western blotting with anti-FLAG (Fig. 3A). MEF2C was clearly detected in the purified preparation of both CDC20 and CDH1, but not in the control immunoprecipitation sample (EV). We observed a slight reduction in the efficiency of association between CDC20 and the 2SA mutant, suggesting that the MEF2C/CDC20 interaction involves the phosphorylation of Ser98 and Ser110. We then tested whether the modulation of CDC20 and CDH1 expression could affect the levels of MEF2C protein wild type or mutated. In C2 proliferating cells we observed that the level of exogenous MEF2C decreased when either CDH1 (90% less protein compared to the control, Fig. 3B right panel) or CDC20 (80% of decrease) over-expression was induced. Furthermore the accumulation of the MEF2C 2SA mutant (30% of decrease) upon ectopic expression of CDC20 indicates that phosphorylation of Ser98 and Ser110 is required for rapid degradation of MEF2C by APC/C<sup>CDC20</sup> but not by APC/C<sup>CDH1</sup> (Fig. 3B). As a control, we found that SKP2, a known substrates of APC/C<sup>CDH137,38</sup> was down-regulated



**Figure 3.** MEF2C protein level is controlled by CDC20 or CDH1, depending on the phosphorylation of Ser98 and Ser110. (A) MEF2C physically interacts with CDC20 and CDH1. Co-immunoprecipitation analysis of Hek293T cells transiently transfected with empty vector (EV) or HA-tagged vectors coding for CDC20 and CDH1 along with FLAG-MEF2C WT or 2SA. 48 hours aftertransfection, cells were treated with MG132 and harvested. Total protein extracts (Input) were incubated with protein A beads conjugated with anti-HA antibody. Left: input. Right: immunoprecipitated proteins: FLAG-tagged MEF2C was detected by Western blotting with anti-FLAG antibody. Vinculin was used as a loading control. Asterisk (\*) indicates non-specific bands. (B) MEF2C expression is reduced by CDC20 and CDH1 overexpression, CDC20 dependent degradation relies on pSer98/pSer110 phosphorylation. C2 proliferating myoblasts were co-transfected with an empty vector (EV) or HA-tagged CDC20 and CDH1 vectors along with phosphorylatable (WT) or not-phosphorylatable (2SA) MEF2C. Cell extracts were analyzed by Western blotting with antibodies against FLAG and HA. Vinculin was used as loading control. The histogram (right panel) reports the densitometric quantification of MEF2C protein level (FLAG signal) normalized to the total amount of protein expressed relatively to the quantity of protein in the control sample, taken as 1. Histograms show means  $\pm$  SEM of 3 independent experiments. \*\* represent *P*-values  $\leq$  0.01. (C) RNAi knockdown of *Cdc20* and/or *Cdh1* results in an accumulation of MEF2C. Asynchronous C2 cells were transfected with a control siRNA (siCTRL) or a pool of siRNAs targeting *Cdh1* (siCdh1, left panel) or *Cdc20* (siCdc20, middle panel) mRNAs and analyzed 72 hours later. Alternatively C2 cells transfected with siCdc20 were treated over-night with Nocodazole after 36 hours from transfection (left panel). Protein extracts were analyzed by Western blotting with antibody against MEF2C, CDH1, CDC20 and histone H3 phosphorylated on Ser10, a marker of the M phase. Vinculin was used as loading control. The results of the Western blot shown in A and C are representative of 2 independent experiments that gave similar profiles.

upon ectopic expression of CDH1 but not CDC20, as shown in **Figure S5**. To further confirm that APC/C<sup>CDC20</sup> and APC/C<sup>CDH1</sup> are required for degradation of endogenous MEF2C, we inhibited their activities by siRNA. Silencing of both *Cdc20* and *Cdh1* transcripts resulted in an increase of the endogenous MEF2C level (**Fig. 3C**). We next tested whether CDC20 is required for MEF2C degradation in mitosis. For this purpose, we silenced *Cdc20* in C2 cells arrested in prometaphase with Nocodazole. As expected, MEF2C protein was downregulated in mitosis in the control sample (**Fig. 3D** siCTRL). In contrast, silencing of *Cdc20* in nocodazole treated cells prevents MEF2C mitotic degradation, restoring a protein level comparable to that of asynchronous cells. Overall our results indicate that APC/C<sup>CDC20</sup> is responsible for the degradation of phosphoSer98 MEF2C in mitosis.


#### D-box, pSer98 and pSer110 motifs are required for CDC20-dependent degradation of MEF2C

Previous studies revealed that APC/C recognizes sequence recognition motifs including a Destruction-box (RXXL; D-box)<sup>39</sup> and/or a KEN-box (KEN).<sup>40</sup> Since our results indicate that MEF2C is a target of APC/C, we tried to identify degradation signals in MEF2C. By sequence analysis, no KEN-boxes were found in the MEF2C  $\alpha 1$  isoform expressed in proliferating muscle cells. On the contrary we identified one putative conserved

D-box motif in the aminoacidic sequence encoded by  $\alpha 1$  exon, proximal to the Ser98 and Ser110 residues (**Fig. 4A**). Indeed we found that the CDC20-dependent degradation of the D-box deleted mutant was lower than that of wild-type MEF2C (**Fig. 4B**, lane 5 compared to lane 2). When both D-box and phosphoacceptor sites were mutated, the protein level was almost completely stabilized (**Fig. 4B**, lane 11). Similar results were obtained using the MEF2C 2SA mutant protein where the D-box arginine and leucine were replaced by alanines (2SA D-box MUT) (**Fig. S6A**). Furthermore we also observed that the MEF2C 2SA D-box deleted protein interacts less efficiently with CDC20 (**Fig. S6B**). On the contrary either the phosphoacceptor sites or the D-box are not required for the CDH1-dependent degradation (lanes 3, 6, 9 and 12). Taken together, a model emerges in which MEF2C establishes a multivalent interaction with CDC20 as both the D-box and the phospho Ser98 and Ser110 motifs are required for APC/C<sup>CDC20</sup>-dependent destruction. Our results also suggest that the phospho Ser98 and Ser110 are the major degradation signals (degrons) for CDC20-dependent degradation.

#### Stabilization of MEF2C impairs progression through mitosis and inhibits CYCLIN B1 nuclear accumulation


Our previous results indicate that MEF2C protein undergoes a mitotic-specific degradation, suggesting that it might have a



**Figure 4.** Ser98/Ser110 phosphorylation and a proximal conserved D-box are required for CDC20-dependent degradation of MEF2C. **(A)** Aminoacid sequence encoded by the  $\alpha 1$  isoform. Sequence of a putative D-box near the Ser98 and Ser110 phosphoacceptor sites. Alignment with ClustalW of the aminoacid sequences encompassing the phosphorylatable residues of MEF2C proteins from different species revealed the presence of a conserved D-box. Aminoacids forming the putative destruction box (D-box) are highlighted in blue, Ser98 and Ser110 in red. The deletion introduced in the MEF2C D-box mutant (MEF2C D-box del) is indicated. **(B)** The D-box and Ser98/Ser110 phosphorylation are all necessary for MEF2C degradation. C2 proliferating myoblasts were co-transfected with an empty vector (EV) or HA-tagged CDC20 and CDH1 vectors along with, alternatively the wild type MEF2C protein (WT), the D-box deleted mutant (WT D-box DEL), the not-phosphorylable MEF2C 2SA mutant or the MEF2C 2SA mutant deleted of the D-box (2SA D-box DEL). Cell extracts were analyzed by Western blotting with antibodies against FLAG and HA. Vinculin was used as loading control.

320 role in the regulation of cell cycle progression. To analyze the biological relevance of MEF2C cell cycle-regulated degradation and to verify whether MEF2C stabilization can affect mitosis, we evaluated the mitotic index of COS cells over-expressing the wild type or the CDC20-resistant MEF2C 2SA mutant. Overexpression of MEF2C 2SA determined a fold15- reduction of the percentage of mitotic cells compared to the wild type protein (Fig. 5A). These data indicated that degradation of MEF2C is important for an efficient progression in mitosis. Since CYCLIN B1 expression, nuclear localization and binding to CDK1 are key events for G2/M transition, we investigated the role of MEF2C phosphorylation in the regulation of CYCLIN B1. Intriguingly,

MEF2C 2SA over expression in HT29 cells, a colorectal cancer (CRC) cell line that expresses low levels of endogenous MEF2C (Fig. 5D), leads to increased cytoplasmic accumulation of CYCLIN B1 (Fig. 5B). Furthermore, our data revealed that ectopic expression of MEF2C induces increased expression of the genes encoding GADD45B, the cyclin-dependent kinase inhibitor p21<sup>Waf1/Cip1</sup> (P21) and 14.3.3  $\gamma$ , all inhibitors of the G2/M transition (Fig. 5C), and this transcriptional effect is more evident with the not degradable 2SA mutant. We then evaluated the impact of MEF2C level fluctuation on cell divisions in CRC cell lines. Consistent with the mitotic effect described above, expression of the stable MEF2C 2SA mutant in HT29 cells, caused a



**Figure 5.** The ectopic expression of a stable, non phosphorylatable mutant of MEF2C can delay cell cycle progression. **(A)** Overexpression of the MEF2C 2SA mutant is linked to a reduced number of mitotic events. COS-1 cells were transfected with vectors coding for wild type MEF2C (WT) or the not-phosphorylatable FLAG-MEF2C 2SA mutant. 48 hours later cells were fixed for immunofluorescence analysis and stained with antibodies for phosphorylated histone H3 and FLAG. Transfected cells were scored for the frequency of mitosis. Histograms show means  $\pm$  SEM of 2 independent experiments. \*\* represent  $P$ -values  $\leq 0.01$ . **(B)** MEF2C 2SA impairs nuclear translocation of CYCLIN B1. HT29 cells transiently transfected with an empty vector (EV) or the expression vectors for the wild type or the not-phosphorylatable MEF2C 2SA mutant were lysed in order to obtain nuclear and cytoplasmic protein extracts. The different fractions were analyzed by Western blotting with CYCLIN B1 antibody. Histone H3 and Vinculin antibodies were used as loading control respectively for nuclear and cytoplasmic fraction. **(C)** MEF2C regulates the expression of genes encoding inhibitors of the G2/(M)transition. Left panel, Total RNA was isolated from transfected C2 cells overexpressing the wild type or 2SA MEF2C protein. The transcripts of *Gadd45b*, *P21* and *14.3.3  $\gamma$*  genes were amplified by RT-PCR, PCR products were separated in 8% polyacrylamide gels (left panel). Rplp0 was used as endogenous control. The histogram in the right panel reports the results of the densitometric quantification of the bands normalized to Rplp0 and expressed relatively to the empty vector transfected cells taken as 1. The RT-PCR results are representative of 2 independent experiments. **(D)** MEF2C is differentially expressed in CRC cell lines. Total protein extracts from HCT116 and HT29 proliferating cells were analyzed by Western blot with antibody against MEF2C. Vinculin was used as loading control. **(E)** MEF2C modulates cell cycle progression in a phosphorylation-dependent manner. HT29 cells were transfected with an empty vector (EV) or vectors coding for the wild type MEF2C protein or the non-phosphorylatable MEF2C 2SA. Twenty-four hours after  $0.1 \times 10^6$  cells were plated for each sample. Cells were then harvested every 24 hours and the number of proliferating cells were counted with a hemacytometer after Trypan blue staining. The graphs show means  $\pm$  SEM of 4 independent experiments. Statistical significance of variation between values obtained at each time points with MEF2C 2SA and MEF2C WT was calculated. Differences between 2SA and WT are statistically significant. \*\* and \*\*\* represent  $P$ -values  $\leq 0.01$  and  $\leq 0.001$  respectively. **(F)** RNAi knockdown of *Mef2c* impairs HCT116 proliferation rate. HCT116 cells were transfected with a control siRNA (siCTRL) or a pool of siRNAs targeting *Mef2c* (siMef2c) and proliferation rate was evaluated as described in E. The graphs show means  $\pm$  SEM of 4 independent experiments. \*\* and \*\*\* represent  $P$ -values  $\leq 0.01$  and  $\leq 0.001$  respectively.

proliferative defect compared to cells transfected with an empty  
vector. In contrast, expression of the wild type MEF2C protein  
promoted cell proliferation (Fig. 5E). Coherently with these  
results, we found that siRNA-mediated silencing of *Mef2c* in  
HCT116 cells, that express high amount of endogenous  
MEF2C, impairs their proliferation rate compared to cells trans-  
fected with a control siRNA (Fig. 5F). Taken together our data  
suggest a model where MEF2C controls, directly or indirectly,  
the expression of genes of the G2/M checkpoint and its degrada-  
tion in the early M Phase is necessary for an efficient progression  
of the cell cycle through mitosis and ultimately for cell  
proliferation.

## Discussion

The MEF2C transcription factor has a key role in the control  
of muscle-specific genes during skeletal muscle terminal differen-  
tiation.<sup>5,6,41</sup> Undifferentiated myoblasts express a splice variant  
of MEF2C, the ubiquitous MEF2C  $\alpha 1$  isoform lacking pro-  
myogenic activity. The function played by this protein in grow-  
ing myoblasts is currently unknown. In the present work, we pro-  
vide evidences that MEF2C is involved in the control of cell cycle  
progression. First we show that the level of MEF2C fluctuates  
during the cell cycle in muscle and non-muscle cells, being tar-  
geted for degradation early in mitosis by the ubiquitin-  
proteasome pathway. Second, we observed that ectopic expres-  
sion of a MEF2C  $\alpha 1$  protein mutant, resistant to mitotic degrada-  
tion, impairs cell cycle progression and results in a lower  
number of cells in mitosis, suggesting a previous unexplored role  
for MEF2C  $\alpha 1$  in the regulation of cell proliferation. Finally we  
observed a modulation of genes that regulate G2/M transition  
upon overexpression of MEF2C.

We present several lines of evidence to indicate that both  
CDC20 and CDH1, the 2 co-activators of APC/C, promote  
MEF2C degradation and that mitotic degradation of MEF2C is  
mediated by APC/C<sup>Cdc20</sup>. Timely downregulation of MEF2C in  
mitosis by APC/C<sup>Cdc20</sup> requires MEF2C phosphorylation of  
Ser98 and Ser110. We found an even level of phosphorylation of  
the MEF2C  $\alpha 1$ -specific Ser110 residue during the cell cycle, this  
phosphoacceptor site is efficiently phosphorylated by CYCLIN  
D1/CDK6 *in vitro*. Whereas Ser98 is phosphorylated in mitosis  
by a yet unknown mitotic kinase. Further, our data indicate that  
a priming phosphorylation of Ser110 is necessary for achieving  
an efficient phosphorylation of Ser98. On the contrary we report  
that APC/C<sup>Cdh1</sup> mediates the down-regulation of MEF2C inde-  
pendently from the status of Ser98 and Ser110 phosphorylation.  
The APC/C<sup>Cdh1</sup> ubiquitin ligase normally regulates exit from  
mitosis and events in G1. Although overexpression of CDH1  
results in a strong decrease of MEF2C, the persistence of some of  
MEF2C following mitosis exit suggests that a subpopulation of  
protein is protected from the CDH1-mediated degradation. We  
speculate that phosphorylation on serine and threonine residues,  
other than Ser98 and Ser110, might protect MEF2C from APC/  
C<sup>CDH1</sup> mediated degradation as described for other targets of  
CDH1.<sup>42-45</sup> The functional relevance of CDH1-mediated

degradation will be subject of future studies. Interestingly, we  
observed APC/C<sup>Cdc20</sup> MEF2C degradation in nocodazole-  
arrested pseudo-prometaphase cells, when the spindle checkpoint  
(SAC) is actively inhibiting CDC20. The escape from SAC inhi-  
bition has been observed also for other APC/C targets such as  
CYCLIN A, Nek2A and HoxC10.<sup>46-49</sup> One proposed model to  
explain the premature degradation of some APC/C<sup>Cdc20</sup> targets  
envisages an increased affinity for CDC20 due to the presence of  
multiple interaction domains in the substrate. Indeed, we found  
that APC/C<sup>Cdc20</sup>-dependent degradation of MEF2C requires a  
conserved D-box together with the 2 phospho-motifs pSer98 and  
pSer110, located in close proximity to the D-box. Notably, the  
D-box and Ser110 residue are located in the protein sequence  
encoded by the ubiquitous alternative exon  $\alpha 1$ , that we and other  
have described to be specifically expressed in proliferating myo-  
blasts (see Fig. 2B and Zhang et al, 2014). We previously  
reported that pSer98 and pSer110 are binding sites for PIN1,<sup>10</sup> a  
peptidyl-prolyl cis-trans isomerase that regulates the activities of  
several phosphor-proteins in mitosis.<sup>50</sup> A possible role played by  
PIN1 in this mechanism warrants future investigations.

Despite the high sequence conservation of the N-terminal  
region among MEF2s, we found that the MEF2C  $\alpha 1$ -specific D-  
box, necessary for CDC20-dependent degrading activity, is not  
present in any other member of the family. Although we cannot  
exclude a cell cycle regulated expression and/or degradation also  
for the other MEF2s, our data prompted us to speculate that the  
CDC20-dependent mitotic degradation is a specific feature of  
MEF2C and particularly of the  $\alpha 1$  isoform. These observations  
together with the recent evidence that individual MEF2s<sup>23,51</sup> and  
alternative splicing isoforms<sup>12</sup> can induce different subsets of  
gene during skeletal muscle differentiation and during develop-  
ment, lead us to speculate about specific biological function(s)  
played by the different members of MEF2 family.

To date, MEF2C protein function in skeletal muscle and in  
other tissues, correlates with their terminal differentiation pro-  
grams.<sup>5,6,41</sup> The fluctuations of its protein level during the cell  
cycle suggest a yet unexplored role in the regulation of cell prolif-  
eration. A cell cycle-regulated expression has been described in  
muscle cells also for MYF5 and MYOD, involved in the control  
of myoblasts proliferation.<sup>31</sup> The observation that the overexpres-  
sion of a non phosphorylatable mutant, resistant to CDC20-  
dependent degradation, impairs mitosis progression means that  
it is plausible that MEF2C can have a role in mitosis regulation.  
Although our data do not clarify whether the reduced number of  
mitotic events is due to a delayed entrance or a faster exit from  
mitosis, we can speculate that MEF2C mutant overexpression  
slows down the transition from G2 phase to mitosis. As a matter  
of fact, upon overexpression of MEF2C, we observed an induc-  
tion of *14-3-3 $\gamma$* , *Gadd45b* and *p21* transcripts, encoding inhibi-  
tors of the CYCLIN B1/CDK1 kinase.<sup>24,52-56</sup> These genes have a  
role in the G2-M checkpoint both in normal cell cycle progres-  
sion and in response to DNA damage. We also found that failure  
of MEF2C degradation correlates with an increase in the cyto-  
plasmic inactive fraction of CYCLIN B1. It has been recently  
reported that MEF2D protein negatively regulates the expression  
of *Gadd45b* and *p21* genes and binds to MEF2 sites in their

promoter sequences in hepatocellular carcinoma (HCC) cell lines.<sup>57</sup> Thus it may be argued that MEF2C induces directly the expression of these G2/M transition inhibitors. In contrast, our bioinformatic analysis did not reveal any MEF2-site in the promoter region of 14–3–3 $\gamma$ , suggesting a possible indirect control of MEF2C on this gene. In addition to the mitotic effect, we observed that over-expression of the non-phosphorylatable MEF2C mutant in low expressing HT29 CRC cells impairs cell proliferation possibly as a consequence of the delayed progression into mitosis, whereas the ectopic expression of wild type MEF2C increases their proliferation rate. Coherently with these observations, we found that knockdown of *Mef2c* expression in high expressing HCT116 cells had a detrimental effect on cell proliferation. Hence MEF2C degradation might be a “sine qua non” condition to achieve mitotic progression and, in turn, to allow cell proliferation. We can hypothesize a positive role of MEF2C in directly stimulating cell cycle progression by activating the transcription of proliferation-related genes such as *c-jun*, a well-known MEF2 target,<sup>19</sup> and/or other yet unknown genes likely related to G1/S transition. This has been recently described by a gene expression analysis study in muscle cells.<sup>23</sup>

In conclusion our work reveal a novel function of MEF2C beyond its well known role in terminal differentiation. According to the classical model MEF2C does not play any specific function in growing myoblasts but is necessary to trigger the differentiation program upon differentiation stimuli. With this work we propose that the ubiquitous MEF2C splice variant plays an active role in promoting, directly or indirectly, the expression of genes that control the G2/M transition thus contributing to the regulation of cell cycle progression.

## Materials and Methods

### Cell culture and synchronization

C2C12, NIH-3T3, COS-1, HEK293T, HCT116 and HT29 cells were cultured in Dulbecco's Modified Eagle's medium, high glucose, GLUTAMAX (Invitrogen) supplemented with 10% fetal bovine serum (Gibco) and 100 U/ml Penicillin/Streptomycin (Euroclone). C2 cells were induced to differentiate, when approaching confluence, with DMEM and 2% horse serum (Hyclone). Cells were cultured at 37°C under a 5% CO<sub>2</sub> atmosphere. The proteasome inhibitor MG132 (Sigma) was added at the indicated concentration 5 hours before harvesting the cells. Transfected COS-1 cells were treated with 25  $\mu$ M cycloheximide (Sigma) in order to assess protein half-life.

C2 cells were synchronized by culturing them in methionine-depleted DMEM medium (Sigma) supplemented with 1% fetal bovine serum, apo-transferrin and sodium selenite (5  $\mu$ g/ml, Sigma). C2 cells were treated over-night with aphidicolin (2,5  $\mu$ g/ml, Sigma) or nocodazole (1  $\mu$ M, Sigma) to obtain respectively S or G2/M phase synchronization. Nocodazole treated cells were subjected to a gentle shake-off in order to collect separately round mitotic cells and G2 adherent cells. Synchronized cells were harvested and DNA distribution analysis was performed after staining with propidium iodide (PI)

(50 mg/ml) with an Epics cytofluorimeter (Beckman Coulter). Cell cycle distribution was analyzed with WinMDI software.

### Proliferation assay

HT29 transfected cells grown in 6 cm plates, were harvested by trypsinization 24 hours after transfection and aliquoted in 12wells plates. For the following 72 hours, cells were harvested every day and the number of proliferating cells was counted with hemacytometer and Typan Blue staining.

### Plasmids and RNA interference

The FLAG tagged MEF2C full-length cDNA (FLAG-MEF2C) and the Ser98 (FLAG-MEF2C S98A), Ser 110 (FLAG-MEF2C S110A) or both the serines (FLAG-MEF2C 2SA) mutants were previously described (Magli et al. 2010). The deletion of the Destruction box (D-box) was obtained by PCR-based site-directed mutagenesis using FLAG-MEF2C or FLAG-MEF2C 2SA as a template, mutations were confirmed by sequencing. The cDNAs deleted of the encoding R<sup>130</sup>XXLXXV<sup>137</sup> were cloned into HindIII-BglII digested pFLAG-CMV (Sigma) with Gibson Assembly Kit (NEB). Plasmid coding for HA-CDC20, HA-CDH1, HA-Ubiquitin and FLAG-SKP2 were kindly provided by Daniele Guardavaccaro (Hubrecht Institute). Transient transfections were performed using Lipofectamine LTX with PLUS Reagent (Invitrogen) according to manufacturer's instruction. For siRNA experiments C2C12 cells were plated in 6-well plates and transfected with the indicated amounts of a pool of 3 siRNAs using RNAiMAX (Invitrogen) following the manufacturer's instruction. Cells were analyzed 48 h after transfection. Silencer siRNAs targeting *Cdh1* (74510, 74322, 165926), *Cdc20* (171932, 171933, 171934), *Mef2c* (157132, 157133, 157134) and Silencer Negative Control #3 siRNA were purchased from Ambion (Life Technologies).

### Western blot analysis and Immunoprecipitation

Total cell extracts were prepared with RIPA buffer (50mMTris HCl pH 7.5, 150mMNaCl, 1mMEDTA, 1% Na Deoxycholate, 1% Igepal, 0.1% SDS, 1mM DTT) supplemented with 1mM phenylmethyl sulfonylflouride (PMSF) and Proteases Inhibitor Complete cocktail (PIC, Roche). Equal amounts of protein extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by Western blot as previously described.<sup>12</sup> The following antibodies were used: mouse monoclonal anti-CYCLIN A (CY-A1), anti-FLAG (M2) and anti-Vinculin (VIN-11-5) from Sigma-Aldrich; mouse monoclonal anti-p55 CDC (E-7) from Santa Cruz Biotechnologies; mouse monoclonal anti-CDH1 (DH01) from Thermo Scientific; mouse monoclonal Phospho-Histone H3 (6G3) from Cell signaling; mouse monoclonal anti-MyHC (MF20) and anti-myogenin (IF5D) from DSHB; rabbit monoclonal anti-MEF2C (D80C1) from Cell Signaling; rabbit polyclonal anti-MEF2C (SBS-002) from Sparrow Biosciences; rabbit polyclonal anti-HA (H6908) from Sigma-Aldrich; rabbit polyclonal anti-MYOD (C-20) and anti-MYF5 (C-20) from Santa Cruz Biotechnologies. Custom polyclonal antibodies against MEF2C phosphorylated on serine 98 (phosphoSer98) or

serine 110 (phosphoSer110) were developed in rabbit using synthetic phosphorylated MEF2C peptide. The antibodies were affinity-purified on the immobilized immunizing MEF2C peptides.

For immunoprecipitation of FLAG tagged proteins, C2C12 cells were harvested 48 hours after transfection and lysed in RIPA buffer supplemented with 1 mM PMSF, PIC, 2,5 mM sodium fluoride (NaF), 1 mM sodium orthovanadate ( $\text{Na}_3\text{VO}_4$ ), 0,5 mM EDTA, 10 mM Iodoacetamide, 2  $\mu\text{M}$  MG132 and 1  $\mu\text{M}$  G5, Ubiquitin Isopeptidase Inhibitor I. Cell extracts were precleared with Protein G Agarose (KPL) and then incubated with anti-FLAG M2 Affinity Gel (Sigma). Immunoprecipitates were washed 4 times in RIPA buffer with inhibitors, eluted by resuspension in Laemmli sample buffer and boiled for 5 minutes. For co-immunoprecipitation HEK293T were treated with 10  $\mu\text{M}$  MG132 for 5 hours and collected 24 hours after transfection. Total cell extracts were prepared by lysis in Triton Lysis Buffer (TLB, 50 mM Tris-HCl pH 7.4, 0.25 M NaCl, 1 mM EDTA, 0.1% Triton X-100, 50 mM NaF) supplemented with 1 mM PMSF, PIC, 1 mM  $\text{Na}_3\text{VO}_4$ , 1 mM (dithiothreitol). Protein G-beads were coated with mouse monoclonal anti-HA (HA7, Sigma) and cell extracts were precleared as described above for 1 hours at 4°C. Cell extract were then incubated with protein G-anti HA coated beads for 3 hours at 4°C. Immunocomplex were washed 4 times with TLB with inhibitors and eluted with Laemmli sample buffer and boiling for 5 minutes.

Protein expression in total extracts and immunoprecipitated or coimmunoprecipitated proteins were analyzed by SDS-PAGE and Western blot as described above.

#### Extraction of cytoplasmic and nuclear protein

Nuclear and cytoplasmic fraction of HT29 transfected cells were obtained with 2 distinct lysis buffer. Briefly cells were washed in cold PBS and harvested in Buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.15% Nonidet P40 (NP40) supplemented with 1 mM DTT and PIC). Cells were homogenized with several passages through a needle 26G, nuclei were sedimented by centrifugation and supernatant containing cytoplasmic protein was conserved. Nuclei were washed quickly with cold PBS, resuspended in Buffer B (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0,5% NP 40 supplemented with 1 mM DTT and PIC) and lysed by sonication. Nuclei lysates were clarified by centrifugation.

#### Immunofluorescence and mitotic index

Immunostaining of COS-1 cells was performed 48 hours after transfection as previously described.<sup>10</sup> Cellular DNA was stained with Hoeascht 33342 (Sigma) and the following primary antibodies were used: mouse monoclonal anti-FLAG M2 (Sigma) and rabbit polyclonal anti-phospho Histone H3 (Ser10) (Millipore). For fluorescent detection anti-mouse and anti-rabbit IgG secondary antibodies conjugated to Alexa Fluor dye (Molecular Probes) were used. All samples were examined in a Zeiss Axioskop 40 fluorescence microscope equipped with an AxioCam HRC camera for image acquisition. Mitotic index estimation

was performed using Cell Counter plugin of Image J (<http://imagej.nih.gov/ij/>) analyzing at last 10 fields for each sample for a total amount of about 200 nuclei.

615

#### Kinase phosphorylation assay

Kinase phosphorylation assay was performed by ProQinase GmbH (Freiburg, Germany). Briefly biotinylated peptides (1  $\mu\text{M}$ ) containing phosphorylatable Serine 98 (KGLNGCDSPDPDA) or Serine 110 (ADDSVGHSPESD) were assayed for phosphorylation in a radiometric assay (33Pan-Qinase<sup>®</sup> Activity Assay) on a panel of 190 Ser/Thr kinases, using streptavidin-coated FlashPlate<sup>®</sup> HTS PLUS plates.

#### RNA extraction and RT-qPCR

Total RNA was isolated with Total RNA Purification Kit (Norgen Biotek) and digested with DNaseI (Invitrogen). 500 ng of RNA were reverse transcribed using Superscript III reverse transcriptase (Invitrogen) according to manufacturer's instruction. The obtained cDNA was qPCR quantified using TaqMan<sup>®</sup> Universal Master Mix II (Applied Biosystems) and the PCR ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems). TaqMan Gene Expression assays for Mef2c transcript and for the normalizer Rplp0 were purchased from Invitrogen.

For quantification of *Gadd45b*, *P21*, *14.3.3 $\gamma$*  and Mef2c  $\alpha 1$  of  $\alpha 2$  isoforms, total RNA was isolated using TRIzol<sup>®</sup> Plus RNA Purification System (Ambion) 48 h hours after transfection, cDNA was obtained and their transcripts analyzed with specific primers. Amplicons were separated in 10% polyacrylamide gel and identified by Ethidium Bromide staining.

Student's t-tests were performed for pairwise comparisons to determine significant differences between groups.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### Acknowledgments

We are highly indebted with Carol Imbriano and Michele Pelosi for their great advises. We thank Marco Crescenzi, Andrea Martello and Domenico D'Arca for very helpful suggestions and discussion. We are grateful to Valentina Basile, Paolo Benatti, Serena Carra, Valentina Salsi and Lucia Montorsi for sharing reagents, protocols and helpful suggestions.

#### Funding

This research was supported in part by Optistem (European collaborative project HEALTH-2007-1.4-6), AFM (Association Francaise contre le Myopathies) (grant n° 16252) and Fondazione di Vignola.

#### Supplemental Material

Supplemental data for this article can be accessed on the publisher's website

## References

- 660 1. Potthoff MJ, Olson EN. MEF2: a central regulator of diverse developmental programs. *Development* 2007; 134:4131-40; PMID:17959722; <http://dx.doi.org/10.1242/dev.008367>
- Q3 665 2. Molkenkin JD, Black BL, Martin JF, Olson EN. Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. *Cell* 1995; 83:1125-36; PMID:8548800; [http://dx.doi.org/10.1016/0092-8674\(95\)90139-6](http://dx.doi.org/10.1016/0092-8674(95)90139-6)
- 670 3. Ornatsky OI, Andreucci JJ, McDermott JC. A dominant-negative form of transcription factor MEF2 inhibits myogenesis. *J Biol Chem* 1997; 272:33271-8; PMID:9407117; <http://dx.doi.org/10.1074/jbc.272.52.33271>
- 675 4. Yu YT, Breitbart RE, Smoot LB, Lee Y, Mahdavi V, Nadal-Ginard B. Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. *Genes Dev* 1992; 6:1783-98; PMID:1516833; <http://dx.doi.org/10.1101/gad.6.9.1783>
- 680 5. Hinitz Y, Hughes SM. Mef2s are required for thick filament formation in nascent muscle fibres. *Development* 2007; 134:2511-9; PMID:1753778; <http://dx.doi.org/10.1242/dev.007088>
- 685 6. Potthoff MJ, Arnold MA, McAnally J, Richardson JA, Bassel-Duby R, Olson EN. Regulation of skeletal muscle sarcomere integrity and postnatal muscle function by Mef2c. *Mol Cell Biol* 2007; 27:8143-51; PMID:17875930; <http://dx.doi.org/10.1128/MCB.01187-07>
- 690 7. Liu N, Nelson BR, Bezprozvannaya S, Shelton JM, Richardson JA, Bassel-Duby R, Olson EN. Requirement of MEF2A, C, and D for skeletal muscle regeneration. *Proc Natl Acad Sci U S A* 2014; 111:4109-14; PMID:24591619; <http://dx.doi.org/10.1073/pnas.1401732111>
- 695 8. Mokalled MH, Johnson AN, Creemers EE, Olson EN. MASTR directs MyoD-dependent satellite cell differentiation during skeletal muscle regeneration. *Genes Dev* 2012; 26:190-202; PMID:22279050; <http://dx.doi.org/10.1101/gad.179663.111>
- 700 9. Angelelli C, Magli A, Ferrari D, Ganassi M, Matafora V, Parise F, Razzini G, Bachi A, Ferrari S, Molinari S. Differentiation-dependent lysine 4 acetylation enhances MEF2C binding to DNA in skeletal muscle cells. *Nucleic Acids Res* 2008; 36:915-28; PMID:18086704; <http://dx.doi.org/10.1093/nar/gkm1114>
- 705 10. Magli A, Angelelli C, Ganassi M, Baruffaldi F, Matafora V, Battini R, Bachi A, Messina G, Rustighi A, Del Sal G, et al. Proline isomerase Pin1 represses terminal differentiation and myocyte enhancer factor 2C function in skeletal muscle cells. *J Biol Chem* 2010; 285:34518-27; PMID:20801874; <http://dx.doi.org/10.1074/jbc.M110.104133>
- 710 11. McKinsey TA, Zhang CL, Olson EN. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. *Mol Cell Biol* 2001; 21:6312-21; PMID:11509672; <http://dx.doi.org/10.1128/MCB.21.18.6312-6321.2001>
- 715 12. Ganassi M, Badodi S, Polacchini A, Baruffaldi F, Battini R, Hughes SM, Hinitz Y, Molinari S. Distinct functions of alternatively spliced isoforms encoded by zebrafish *mef2ca* and *mef2cb*. *Biochim Biophys Acta* 2014; 1839:559-70; PMID:24844180; <http://dx.doi.org/10.1016/j.bbagr.2014.05.003>
- 720 13. Zhu B, Gulick T. Phosphorylation and alternative pre-mRNA splicing converge to regulate myocyte enhancer factor 2C activity. *Mol Cell Biol* 2004; 24:8264-75; PMID:15340086; <http://dx.doi.org/10.1128/MCB.24.18.8264-8275.2004>
- 730 14. Zhu B, Ramachandran B, Gulick T. Alternative pre-mRNA splicing governs expression of a conserved acidic transactivation domain in myocyte enhancer factor 2 factors of striated muscle and brain. *J Biol Chem* 2005; 280:28749-60; PMID:15834131; <http://dx.doi.org/10.1074/jbc.M502491200>
15. Zhang M, Zhu B, Davie J. Alternative splicing of MEF2C controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells. *J Biol Chem* 2014; 290:310-24; PMID:25404735
16. McDermott JC, Cardoso MC, Yu YT, Andres V, Leifer D, Krainc D, Lipton SA, Nadal-Ginard B. hMEF2C gene encodes skeletal muscle- and brain-specific transcription factors. *Mol Cell Biol* 1993; 13:2564-77; PMID:8455629
17. Coso OA, Montaner S, Fromm C, Lacal JC, Prywes R, Teramoto H, Gutkind JS. Signaling from G protein-coupled receptors to the c-jun promoter involves the MEF2 transcription factor. Evidence for a novel c-jun amino-terminal kinase-independent pathway. *J Biol Chem* 1997; 272:20691-7; PMID:9252389; <http://dx.doi.org/10.1074/jbc.272.33.20691>
18. Wilker PR, Kohyama M, Sandau MM, Albring JC, Nakagawa O, Schwarz JJ, Murphy KM. Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. *Nat Immunol* 2008; 9:603-12; PMID:18438409; <http://dx.doi.org/10.1038/ni.1609>
19. Han TH, Prywes R. Regulatory role of MEF2D in serum induction of the c-jun promoter. *Mol Cell Biol* 1995; 15:2907-15; PMID:7760790
20. Clarke N, Arenzana N, Hai T, Minden A, Prywes R. Epidermal growth factor induction of the c-jun promoter by a Rac pathway. *Mol Cell Biol* 1998; 18:1065-73; PMID:9448004
21. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. *EMBO J* 1997; 16:7054-66; PMID:9384584; <http://dx.doi.org/10.1093/emboj/16.23.7054>
22. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. *Nature* 1998; 395:713-6; PMID:9790194; <http://dx.doi.org/10.1038/27234>
23. Estrella NL, Desjardins CA, Nocco SE, Clark AL, Maksimenko Y, Naya FJ. MEF2 transcription factors regulate distinct gene programs in mammalian skeletal muscle differentiation. *J Biol Chem* 2014; 290:1256-68; PMID:25416778
24. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science* 1998; 282:1497-501; PMID:9822382; <http://dx.doi.org/10.1126/science.282.5393.1497>
25. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. *Mol Cell* 1997; 1:3-11; PMID:9659898; [http://dx.doi.org/10.1016/S1097-2765\(00\)80002-7](http://dx.doi.org/10.1016/S1097-2765(00)80002-7)
26. Jin S, Tong T, Fan W, Fan F, Antinore MJ, Zhu X, Mazzacurati L, Li X, Petrik KL, Rajasekaran B, et al. GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. *Oncogene* 2002; 21:8696-704; PMID:12483522; <http://dx.doi.org/10.1038/sj.onc.1206034>
27. Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. *Nature* 1977; 270:725-7; PMID:563524; <http://dx.doi.org/10.1038/sj.onc.1206034>
28. Kitzmann M, Fernandez A. Crosstalk between cell cycle regulators and the myogenic factor MyoD in skeletal myoblasts. *Cell Mol Life Sci* 2001; 58:571-9; PMID:11361092; <http://dx.doi.org/10.1007/PL00000882>
29. Ridgeway AG, Wilton S, Skerjanc IS. Myocyte enhancer factor 2C and myogenin up-regulate each other's expression and induce the development of skeletal muscle in P19 cells. *J Biol Chem* 2000; 275:41-6; PMID:10617583; <http://dx.doi.org/10.1074/jbc.275.1.41>
30. Doucet C, Gutierrez GJ, Lindon C, Lorca T, Lledo G, Pinset C, Coux O. Multiple phosphorylation events control mitotic degradation of the muscle transcription factor Myf5. *BMC Biochem* 2005; 6:27; PMID:16321160; <http://dx.doi.org/10.1186/1471-2091-6-27>
31. Kitzmann M, Carnac G, Vandromme M, Primig M, Lamb NJ, Fernandez A. The muscle regulatory factors MyoD and myf-5 undergo distinct cell cycle-specific expression in muscle cells. *J Cell Biol* 1998; 142:1447-59; PMID:9744876; <http://dx.doi.org/10.1083/jcb.142.6.1447>
32. Lindon C, Montarras D, Pinset C. Cell cycle-regulated expression of the muscle determination factor Myf5 in proliferating myoblasts. *J Cell Biol* 1998; 140:111-8; PMID:9425159; <http://dx.doi.org/10.1083/jcb.140.1.111>
33. Batonnet-Pichon S, Tintignac LJ, Castro A, Sirri V, Leibovitch MP, Lorca T, Leibovitch SA. MyoD undergoes a distinct G2/M-specific regulation in muscle cells. *Exp Cell Res* 2006; 312:3999-4010; PMID:17014844; <http://dx.doi.org/10.1016/j.yexcr.2006.09.001>
34. Song A, Wang Q, Goebel MG, Harrington MA. Phosphorylation of nuclear MyoD is required for its rapid degradation. *Mol Cell Biol* 1998; 18:4994-9; PMID:9710583
35. Tintignac LA, Sirri V, Leibovitch MP, Lecluse Y, Castedo M, Metivier D, Kroemer G, Leibovitch SA. Mutant MyoD lacking Cdc2 phosphorylation sites delays M-phase entry. *Mol Cell Biol* 2004; 24:1809-21; PMID:14749395; <http://dx.doi.org/10.1128/MCB.24.4.1809-1821.2004>
36. Yu H. Regulation of APC-Cdc20 by the spindle checkpoint. *Curr Opin Cell Biol* 2002; 14:706-14; PMID:12473343; [http://dx.doi.org/10.1016/S0955-0674\(02\)00382-4](http://dx.doi.org/10.1016/S0955-0674(02)00382-4)
37. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. *Nature* 2004; 428:190-3; PMID:15014502; <http://dx.doi.org/10.1038/nature02330>
38. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin WG Jr. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. *Nature* 2004; 428:194-8; PMID:15014503; <http://dx.doi.org/10.1038/nature02381>
39. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. *Nature* 1991; 349:132-8; PMID:1846030; <http://dx.doi.org/10.1038/349132a0>
40. Pflieger CM, Kirschner MW. The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1. *Genes Dev* 2000; 14:655-65; PMID:10733526
41. Hinitz Y, Pan L, Walker C, Dowd J, Moens CB, Hughes SM. Zebrafish *Mef2ca* and *Mef2cb* are essential for both first and second heart field cardiomyocyte differentiation. *Dev Biol* 2012; 369:199-210; PMID:22750409; <http://dx.doi.org/10.1016/j.ydbio.2012.06.019>
42. Gao D, Inuzuka H, Tseng A, Chin RY, Toker A, Wei W. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APC/Cdh1-mediated Skp2 destruction. *Nat Cell Biol* 2009; 11:397-408; PMID:19270695; <http://dx.doi.org/10.1038/ncb1847>
43. Littlepage LE, Ruderman JV. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. *Genes Dev* 2002; 16:2274-85; PMID:12208850; <http://dx.doi.org/10.1101/gad.1007302>
44. Mailand N, Diffley JF. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6

- 735 from APC/C-dependent proteolysis. *Cell* 2005; 122:915-26; PMID:16153703; <http://dx.doi.org/10.1016/j.cell.2005.08.013>
45. Rodier G, Coulombe P, Tanguay PL, Boutonnet C, Meloche S. Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from degradation by APC(Cdh1) in G1 phase. *EMBO J* 2008; 27:679-91; PMID:18239684; <http://dx.doi.org/10.1038/emboj.2008.6>
- 740 46. den Elzen N, Pines J. Cyclin A is destroyed in prometaphase and can delay chromosome alignment and anaphase. *J Cell Biol* 2001; 153:121-36; PMID:11285279; <http://dx.doi.org/10.1083/jcb.153.1.121>
- 745 47. Gabellini D, Colaluca IN, Vodermaier HC, Biamonti G, Giacca M, Falaschi A, Riva S, Peverali FA. Early mitotic degradation of the homeoprotein HOXC10 is potentially linked to cell cycle progression. *EMBO J* 2003; 22:3715-24; PMID:12853486; <http://dx.doi.org/10.1093/emboj/cdg340>
- 750 48. Geley S, Kramer E, Gieffers C, Gannon J, Peters JM, Hunt T. Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. *J Cell Biol* 2001; 153:137-48; PMID:11285280; <http://dx.doi.org/10.1083/jcb.153.1.137>
- 755 49. Hames RS, Wattam SL, Yamano H, Bacchieri R, Fry AM. APC/C-mediated destruction of the centrosomal kinase Nek2A occurs in early mitosis and depends upon a cyclin A-type D-box. *EMBO J* 2001; 20:7117-27; PMID:11742988; <http://dx.doi.org/10.1093/emboj/20.24.7117>
50. Shen M, Stukenberg PT, Kirschner MW, Lu KP. The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. *Genes Dev* 1998; 12:706-20; PMID:9499405; <http://dx.doi.org/10.1101/gad.12.5.706>
51. Wales S, Hashemi S, Blais A, McDermott JC. Global MEF2 target gene analysis in cardiac and skeletal muscle reveals novel regulation of DUSP6 by p38MAPK-MEF2 signaling. *Nucleic Acids Res* 2015; 42:11349-62; <http://dx.doi.org/10.1093/nar/gku813>
52. Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, Augeri-Henmueller L, Shehee R, Molinaro TA, Kim KE, Tolosa E, Ashwell JD, et al. Genomic instability in Gadd45a-deficient mice. *Nat Genet* 1999; 23:176-84; PMID:10508513; <http://dx.doi.org/10.1038/13802>
53. Hosing AS, Kundu ST, Dalal SN. 14-3-3 Gamma is required to enforce both the incomplete S phase and G2 DNA damage checkpoints. *Cell Cycle* 2008; 7:3171-9; PMID:18843201; <http://dx.doi.org/10.4161/cc.7.20.6812>
54. Kasahara K, Goto H, Enomoto M, Tomono Y, Kiyono T, Inagaki M. 14-3-3gamma mediates Cdc25A proteolysis to block premature mitotic entry after DNA damage. *EMBO J* 2010; 29:2802-12; PMID:20639859; <http://dx.doi.org/10.1038/emboj.2010.157>
55. Lee JH, Lu H. 14-3-3Gamma inhibition of MDMX-mediated p21 turnover independent of p53. *J Biol Chem* 2011; 286:5136-42; PMID:21148311; <http://dx.doi.org/10.1074/jbc.M110.190470>
56. Vairapandi M, Balliet AG, Hoffman B, Liebermann DA. GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress. *J Cell Physiol* 2002; 192:327-38; PMID:12124778; <http://dx.doi.org/10.1002/jcp.10140>
57. Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y, Xia F, Shan J, Shen J, Yang Z, et al. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. *Cancer Res* 2014; 74:1452-62; PMID:24390737; <http://dx.doi.org/10.1158/0008-5472.CAN-13-2171>